Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular eve...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Sci Transl Med
Glavni autori: Bovijn, Jonas, Krebs, Kristi, Chen, Chia-Yen, Boxall, Ruth, Censin, Jenny C., Ferreira, Teresa, Pulit, Sara L., Glastonbury, Craig A., Laber, Samantha, Millwood, Iona Y., Lin, Kuang, Li, Liming, Chen, Zhengming, Milani, Lili, Smith, George Davey, Walters, Robin G., Mägi, Reedik, Neale, Benjamin M., Lindgren, Cecilia M., Holmes, Michael V.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116615/
https://ncbi.nlm.nih.gov/pubmed/32581134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aay6570
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items